Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivo

Fig. 4

Enhanced LDH release in MDA-MB-231 cells treated with AsIII combined with Tetra. After treatment with 10 μM AsIII and 4 μg/ml Tetra, alone or in combination, in the presence or absence of 0.25 μM wortmannin, for 48 h, LDH leakage was measured using the LDH-Cytotoxic test kit as described under “Materials and methods”. Significant difference between control and treatment with AsIII and Tetra, alone or in combination, are shown (p < 0.0001 vs. control; p < 0.0001 vs. AsIII alone; p < 0.001 vs. Tetra). As, AsIII; Tetra, tetrandrine

Back to article page